<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: <z:chebi fb="0" ids="8228">Pioglitazone</z:chebi>, <z:chebi fb="0" ids="6801">metformin</z:chebi>, and <z:chebi fb="0" ids="31654">gliclazide</z:chebi> lower HbA(1c) and fasting plasma <z:chebi fb="105" ids="17234">glucose</z:chebi> in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>We compared the effects of these three drugs, used as monotherapy and in combination, on postload glycemia and composite insulin sensitivity index (CISI) in these patients </plain></SENT>
<SENT sid="2" pm="."><plain>RESEARCH DESIGN AND METHODS: Postload glycemia and CISI were analyzed for 940 patients who had oral <z:chebi fb="105" ids="17234">glucose</z:chebi> tolerance tests (OGTTs) in four multicenter, randomized, double-blind, double-dummy, parallel group clinical trials (<z:chebi fb="0" ids="8228">pioglitazone</z:chebi> versus <z:chebi fb="0" ids="6801">metformin</z:chebi>, <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> versus <z:chebi fb="0" ids="31654">gliclazide</z:chebi>, <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> plus <z:chebi fb="0" ids="26831">sulfonylurea</z:chebi> versus <z:chebi fb="0" ids="6801">metformin</z:chebi> plus <z:chebi fb="0" ids="26831">sulfonylurea</z:chebi>, and <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> plus <z:chebi fb="0" ids="6801">metformin</z:chebi> versus <z:chebi fb="0" ids="31654">gliclazide</z:chebi> plus <z:chebi fb="0" ids="6801">metformin</z:chebi>) </plain></SENT>
<SENT sid="3" pm="."><plain>Plasma <z:chebi fb="105" ids="17234">glucose</z:chebi> and insulin were determined during the 3-h OGTT performed at baseline and after 1 year of therapy </plain></SENT>
<SENT sid="4" pm="."><plain>Incremental area under the curve for <z:chebi fb="105" ids="17234">glucose</z:chebi> was the surrogate for postload glycemia </plain></SENT>
<SENT sid="5" pm="."><plain>CISI was calculated using the formula {10,000/ radical of [(fasting <z:chebi fb="105" ids="17234">glucose</z:chebi> x fasting insulin) x (mean <z:chebi fb="105" ids="17234">glucose</z:chebi> x mean insulin)]} during the OGTT </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: In monotherapy, <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> reduced postload glycemia and enhanced CISI more than <z:chebi fb="0" ids="6801">metformin</z:chebi> and <z:chebi fb="0" ids="31654">gliclazide</z:chebi> </plain></SENT>
<SENT sid="7" pm="."><plain>In combination therapy, <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> plus <z:chebi fb="0" ids="26831">sulfonylurea</z:chebi> reduced postload glycemia and increased CISI more than <z:chebi fb="0" ids="6801">metformin</z:chebi> plus <z:chebi fb="0" ids="26831">sulfonylurea</z:chebi> </plain></SENT>
<SENT sid="8" pm="."><plain><z:chebi fb="0" ids="8228">Pioglitazone</z:chebi> plus <z:chebi fb="0" ids="6801">metformin</z:chebi> also decreased postload glycemia and increased CISI more than <z:chebi fb="0" ids="31654">gliclazide</z:chebi> plus <z:chebi fb="0" ids="6801">metformin</z:chebi> </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: <z:chebi fb="0" ids="8228">Pioglitazone</z:chebi> improves postload glycemia and CISI more than <z:chebi fb="0" ids="6801">metformin</z:chebi> or <z:chebi fb="0" ids="31654">gliclazide</z:chebi> when used as monotherapy or in combination therapy in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
</text></document>